Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
<p><strong>BACKGROUND:</strong> Inhaled budesonide has shown efficacy for treating COVID-19 in the community but has not yet been tested in effectiveness trials.</p> <p><strong>METHODS:</strong> We performed a multicenter, open-label, multi-arm, adaptive pl...
Main Authors: | Yu, L-M, Ramakrishnan, S, Bafadhel, M, Dorward, J, Hayward, G, Saville, BR, Gbinigie, O, van Hecke, O, Ogburn, E, Evans, PH, Thomas, NPB, Patel, MG, Berry, N, Detry, MA, Saunders, CT, Fitzgerald, M, Harris, V, de Lusignan, S, Andersson, MI, Barnes, PJ, Russell, REK, Nicolau, DV, Hobbs, FDR, Butler, CC |
---|---|
Other Authors: | PRINCIPLE Collaborative Group |
Format: | Journal article |
Language: | English |
Published: |
Cold Spring Harbor Laboratory
2021
|
Similar Items
-
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
by: Yu, L-M, et al.
Published: (2021) -
High-dose budesonide for early COVID-19 - Authors' reply
by: Hobbs, FDR, et al.
Published: (2021) -
Inhaled budesonide for COVID-19 in people at higher risk of complications in the community: the UK National Community Randomi
by: Gbinigie, O, et al.
Published: (2023) -
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
by: PRINCIPLE Trial Collaborative Group, et al.
Published: (2021) -
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
by: Butler, CC, et al.
Published: (2021)